Bayer submits EU marketing application for menopause relief drug

(Reuters) – Bayer on Tuesday said it had applied for marketing authorization with the European Medicines Agency (EMA) for its menopause relief drug elinzanetant.

The daily pill was shown to ease hot flashes in a third late-stage trial that provided supporting data on efficacy and long-term safety.

(Reporting by Andrey Sychev, Editing by Friederike Heine)